Protective effect of pentoxyfilline in renal toxicity after methotrexate administration

I Asvadi1, B Hajipour, A Asvadi

  • 1Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Abstract

Insights

Pentoxifylline (PTX) protects against Methotrexate (MTX)-induced kidney damage by reducing oxidative stress and inflammation. This study demonstrates PTX

Area of Science:

  • Nephrology
  • Pharmacology
  • Toxicology

Background:

  • Methotrexate (MTX) treatment can cause nephrotoxicity, a significant clinical concern.
  • Pentoxifylline (PTX) possesses anti-inflammatory and antioxidant properties.
  • This study investigates PTX's potential to mitigate MTX-induced renal damage.

Purpose of the Study:

  • To evaluate the protective effects of Pentoxifylline (PTX) against Methotrexate (MTX)-induced nephrotoxicity in a rat model.
  • To explore the underlying mechanisms involving TNF-alpha downregulation and improved cellular antioxidant activity.

Main Methods:

  • Forty-five male Wistar rats were divided into three groups: control, MTX-treated, and MTX + PTX-treated.
  • MTX (20 mg/kg) was administered intraperitoneally; PTX (50 mg/kg) was given for 3 days prior to and 6 days after MTX.
  • Renal tissues and serum were collected for biochemical and histological analysis, including oxidative stress markers and TNF-alpha levels.

Main Results:

  • MTX administration significantly increased renal tissue injury, apoptosis (TUNEL-positive cells), malondialdehyde (MDA) levels, and serum BUN and creatinine.
  • Simultaneously, MTX treatment reduced glutathione peroxidase (GPx) and superoxide dismutase (SOD) activities.
  • PTX co-administration significantly attenuated these MTX-induced detrimental effects, lowering MDA, BUN, creatinine, and TNF-alpha, while preserving GPx and SOD activity.

Conclusions:

  • MTX-induced renal toxicity appears to be related to direct cellular damage rather than folate synthesis inhibition.
  • Pentoxifylline (PTX) demonstrated significant renoprotective effects against MTX toxicity by reducing oxidative stress and apoptosis.
  • Further research is warranted to fully elucidate the mechanisms of MTX nephrotoxicity and PTX's protective role.

Related Concept Videos

Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmaceutical Poisoning: Treatment Strategies01:26

Pharmaceutical Poisoning: Treatment Strategies

Treatment strategies for poisoning are a critical aspect of emergency medicine, focusing on preventing the absorption of toxins and enhancing their elimination. When a poisoning incident occurs, the first response is to halt exposure and decontaminate the patient, particularly through gastrointestinal (GI) methods if the poison was ingested.Gastrointestinal Decontamination Techniques:Activated charcoal is the cornerstone of GI decontamination. It works through adsorption, binding the toxin to...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...